Cofactor Genomics
Cofactor Genomics reads the RNA of a tumour sample to model the immune cells inside it, and uses that to predict who will respond to immunotherapy.
Overview
Cofactor Genomics builds RNA-based diagnostics using what it calls Predictive Immune Modeling: multidimensional RNA expression models of the tumour immune microenvironment trained on large datasets. Its OncoPrism assay is intended to predict response to checkpoint inhibitors, with validation work presented in head and neck and other solid tumours and analytical validation published in molecular diagnostics journals. The company is CAP and CLIA accredited and, per its YC profile, is backed by Menlo Ventures, DCVC and Ascension Ventures. Evidence is at the clinical validation stage rather than randomised proof of benefit.
Funding
All startupsPages like this
not linked directly; found by shared links- CompanySignatur Biosciences
Shares Y Combinator, Companion diagnostics and the tag yc.
- CompanyOncobox
Shares Y Combinator, RNA sequencing & expression profiling and the tag yc.
- CompanyBlank Bio
Shares Y Combinator, RNA sequencing & expression profiling and the tag yc.
- CompanyData Driven Bioscience (Duoseq)
Shares Y Combinator, RNA sequencing & expression profiling and the tag yc.
- CompanyArpeggio Bio
Shares Y Combinator, RNA sequencing & expression profiling and the tag yc.
- CompanyIsabl
Shares Y Combinator, RNA sequencing & expression profiling and the tag yc.
- CompanyAluna
Shares Y Combinator and the tag yc.
- CompanyLiyfe
Shares Y Combinator and the tag yc.